Preliminary Phase 3 trial results from Russia’s Sputnik V vaccine shows that it’s 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease.

The trial also found that the 2,144 people over the age of 60 tolerated the vaccine well, and the vaccine had a similar efficacy of 91.8%. Out of the total 19,866 participants, 16 cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after the first vaccine dose. Sixty-two cases were found in the placebo group, which equated to efficacy of 91.6%. There were also no adverse reactions associated with the vaccine, while mild symptoms were found, including pain at the injection site, flu-like symptoms, and low energy levels. The trial is currently ongoing and is aiming to include a total of 40,000 participants, including a more diverse panel of participants, as most of the participants in the trial were also white.